Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide
Authors' conclusion
Renal impairment did not appear to have a clinically relevant impact on the PK or safety profile of zenagamtide
Study context
- Population
- Adults with BMI 20.0–39.9 kg/m², categorised by baseline renal status (CKD-EPI creatinine equation 2021); single SC dose of zenagamtide 0.3 mg, 4-week follow-up
- Participants
- 42 adults
- Comparison
- Renal impairment vs normal renal function
- Normal renal functionn = 14reference
- Mild impairmentn = 7
- Moderate impairmentn = 7
- Severe impairmentn = 7
- End-stage renal disease (ESRD)n = 7
- Outcome
- Zenagamtide plasma AUC from time zero to infinity (AUC0-∞)
Methodological detailssingle dose, open-label not stated
- Single dose
- Open-label not stated
Main finding
As reported in the abstract
AUC0-∞ (geometric mean)
Normal renal function
543
geometric mean · h × nmol/L
- AUC0-∞ geometric mean range across renal impairment groups
- 520-715 h × nmol/L
Further findings
| Outcome | Values |
|---|---|
| Cmax (geometric mean) | Normal renal function geometric mean 3.2 nmol/L |
- Cmax (geometric mean) — Cmax geometric mean range across renal impairment groups
- 2.8-3.5 nmol
Safety
- Participants with treatment-emergent adverse events (TEAEs), overall
- 30 (71.4%)
- Severe TEAEs
- 0
- TEAEs non-serious, mostly mild and most often gastrointestinal
Original publication
Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide. Diabetes Obes Metab. Published 13 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →